Sonnet BioTherapeutics Holdings, Inc. - Common Stock (SONN)
3.9200
-0.2300 (-5.54%)
NASDAQ · Last Trade: Jul 3rd, 2:35 PM EDT
Detailed Quote
Previous Close | 4.150 |
---|---|
Open | 3.650 |
Bid | 4.550 |
Ask | 4.600 |
Day's Range | 3.100 - 4.140 |
52 Week Range | 1.080 - 10.02 |
Volume | 5,647,497 |
Market Cap | 12.41M |
PE Ratio (TTM) | -0.2895 |
EPS (TTM) | -13.5 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 5,945,047 |
Chart
About Sonnet BioTherapeutics Holdings, Inc. - Common Stock (SONN)
Sonnet Biotherapeutics Holdings Inc is a biotechnology company focused on the development of innovative therapies for various diseases, particularly in the field of immuno-oncology. The company leverages its proprietary technology platform to create biologic drugs that aim to harness the body's immune system to target and eliminate cancer cells. Through a combination of advanced engineering and scientific expertise, Sonnet is working to deliver novel treatments that could provide meaningful benefits to patients in need, addressing unmet medical needs in oncology and other therapeutic areas. Read More
News & Press Releases
The trading volume of these stocks is deviating from the norm in today's session.
Via Chartmill · July 3, 2025
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · July 3, 2025
Via Benzinga · July 3, 2025
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · July 3, 2025
Via Benzinga · July 3, 2025
Via Benzinga · July 3, 2025
Via Benzinga · July 2, 2025
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · July 2, 2025
Via Benzinga · July 2, 2025

Via Benzinga · May 28, 2025

Via Benzinga · May 28, 2025
Via Benzinga · April 24, 2025

Via Benzinga · December 9, 2024

Via Benzinga · November 6, 2024

Via Benzinga · November 6, 2024

Via Benzinga · November 6, 2024

Via Benzinga · October 28, 2024

Via Benzinga · October 28, 2024

Via Benzinga · October 17, 2024

Via Benzinga · September 26, 2024

Sonnet BioTherapeutics shares are trading lower by 15.5% Wednesday afternoon. The company announced a 1-for-8 reverse stock split.
Via Benzinga · September 25, 2024

Via Benzinga · August 16, 2024

SONN stock results show that Sonnet BioTherapeutics beat analyst estimates for earnings per share the third quarter of 2024.
Via InvestorPlace · August 14, 2024